Clovis Oncology Inc (NASDAQ:CLVS) Sinking But Getting Attractive

Dec. 05, 2017 12:44 PM ETClovis Oncology, Inc. (CLVS)
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2009

InTheMoneyStocks.Com is a research and consulting company focused on mathematical proprietary techniques along with a key understanding of price, pattern and time. Through understanding geometry and other technical analysis methods, InTheMoneyStocks.Com prides itself on avoiding Wall Street hype while calling major and minor moves in the DOW, NASDAQ and S&P, commodities, currencies and stocks. Mission Statement: Our goal is to provide accurate and precise market guidance without the Wall Street hype.

Clovis Oncology Inc (NASDAQ:CLVS) is leading biotechnology company that is focused on developing and commercializing anti-cancer agents globally. This stock has been under pressure since peaking on July 1, 2017. At that time, CLVS stock traded as high as $99.45 a share. Today, the stock is trading around $59.00 a share. This is about a 40.0 percent decline in the stock in the past six months.

The stock is now trading down towards its 200-week moving average. This important moving average is around the $55.00 level. This area should serve as major chart support when it is tested. This is a very attractive area for a bounce in the stock. Now please understand, all biotechnology stocks do have a lot of risk in them. So the way that I will trade the stock will probably be with a call option. By using options I will simply be risking the premium paid for the call option, therefore knowing my maximum loss if I'm wrong on the trade. The positive upside of using a call options is that the potential percentage gain will be much greater than if I actually bought the stock outright.



Nicholas Santiago

InTheMoneyStocks

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.